Filing search / Lyell Immunopharma, Inc. / "Innovate"

Search information

Lyell Immunopharma, Inc.

Companies

"Innovate"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

13 results

Newest first Best match first

10-Q

2024 Q3

LYEL Lyell Immunopharma, Inc.

Quarterly report

. LYL797 was enhanced with c-Jun overexpression and manufactured with our Epi-R protocol. A key pillar of our strategy is to continually innovate … are also advancing multiple strategic alternatives to innovate and scale manufacturing in the future. We are evaluating third-party manufacturing options

7 Nov 24

4:16pm

10-Q

2024 Q2

LYEL Lyell Immunopharma, Inc.

Quarterly report

-exhaustion technologies designed for enhanced potency A key pillar of our strategy is to continually innovate to develop and advance novel, breakthrough … commercialization, we are also advancing multiple strategic alternatives to innovate and scale manufacturing in the future. We are evaluating third-party

7 Aug 24

4:10pm

10-Q

2024 Q1

LYEL Lyell Immunopharma, Inc.

Quarterly report

reprogramming technologies designed for enhanced cytotoxicity A key pillar of our strategy is to continually innovate to develop and advance novel … alternatives to innovate and scale manufacturing in the future. We are evaluating third-party manufacturing options, such as the recently initiated CAR T-cell

6 May 24

8:06am

10-K

2023 FY

LYEL Lyell Immunopharma, Inc.

Annual report

. Continually innovate to develop and advance novel, breakthrough technologies for cell therapy — We are committed to continuing to discover, develop and advance … to patients with cancer. Maintain state‑of‑the‑art infrastructure and expert capabilities to control and innovate cell product manufacturing — We have

28 Feb 24

4:13pm

10-Q

2023 Q3

LYEL Lyell Immunopharma, Inc.

Quarterly report

CAR T-cell product designed for enhanced cytotoxicity. A key pillar of our strategy is to continually innovate to develop and advance novel

7 Nov 23

4:14pm

10-Q

9j0vd725u m5

Quarterly report

8 Aug 23

4:21pm

10-Q

6lyyqg p3589

Quarterly report

4 May 23

4:20pm

Prospectus supplement with pricing info

IPO registration (amended)

Draft registration statement (amended)

Draft registration statement

12:00am

Filing search / Lyell Immunopharma, Inc. / "Innovate"

13 results

Top filers

Top filing types

Recent filing years